LXR-623, a liver X receptor (LXR) β agonist, selectively kills GBM cells by inhibiting low-density lipoprotein receptor (LDLR) expression to reduce cholesterol uptake and promoting ATP-binding cassette subfamily A member 1 (ABCA1) expression to increase cholesterol efflux. Here, LDLR is linked to glioblastoma.